133 related articles for article (PubMed ID: 23132699)
21. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
22. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):386-7. PubMed ID: 20611009
[No Abstract] [Full Text] [Related]
23. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
24. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
[TBL] [Abstract][Full Text] [Related]
25. Metastatic type 1 gastric carcinoid: a real threat or just a myth?
Grozinsky-Glasberg S; Thomas D; Strosberg JR; Pape UF; Felder S; Tsolakis AV; Alexandraki KI; Fraenkel M; Saiegh L; Reissman P; Kaltsas G; Gross DJ
World J Gastroenterol; 2013 Dec; 19(46):8687-95. PubMed ID: 24379587
[TBL] [Abstract][Full Text] [Related]
26. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours.
Murugesan SV; Steele IA; Dimaline R; Poston GJ; Shrotri M; Campbell F; Varro A; Pritchard DM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):474-81. PubMed ID: 23249603
[TBL] [Abstract][Full Text] [Related]
27. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.
Manfredi S; Pagenault M; de Lajarte-Thirouard AS; Bretagne JF
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):1021-5. PubMed ID: 18049175
[TBL] [Abstract][Full Text] [Related]
28. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
29. Multiple carcinoid tumors of the stomach with hypergastrinemia.
Nosaka T; Habu H; Endo M; Okayasu I
Am J Gastroenterol; 1992 Jun; 87(6):766-70. PubMed ID: 1590318
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia.
Hoshino M; Omura N; Yano F; Tsuboi K; Matsumoto A; Yamamoto SR; Akimoto S; Kashiwagi H; Yanaga K
Hepatogastroenterology; 2010; 57(98):379-82. PubMed ID: 20583448
[TBL] [Abstract][Full Text] [Related]
31. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan.
Sato Y; Imamura H; Kaizaki Y; Koizumi W; Ishido K; Kurahara K; Suzuki H; Fujisaki J; Hirakawa K; Hosokawa O; Ito M; Kaminishi M; Furuta T; Chiba T; Haruma K
Dig Endosc; 2014 May; 26(3):377-84. PubMed ID: 24188531
[TBL] [Abstract][Full Text] [Related]
32. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
33. Multiple gastric carcinoids associated with hypergastrinemia. A review of five cases with clinicopathological analysis and surgical strategies.
Okada K; Kijima H; Chino O; Matsuyama M; Okamoto Y; Yamamoto S; Tanaka M; Inokuchi S; Makuuchi H
Anticancer Res; 2005; 25(6C):4417-22. PubMed ID: 16334119
[TBL] [Abstract][Full Text] [Related]
34. Metastatic carcinoid tumor: changing patterns of care over two decades.
Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
[TBL] [Abstract][Full Text] [Related]
35. Long-term octreotide treatment of metastatic carcinoid tumor.
Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G
Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473
[TBL] [Abstract][Full Text] [Related]
36. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
37. [Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis].
Somogyi A; Ruzicska E; Varga T; Rácz K; Nagy G
Orv Hetil; 2007 Sep; 148(35):1667-71. PubMed ID: 17720674
[TBL] [Abstract][Full Text] [Related]
38. En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy.
Hopper AD; Bourke MJ; Hourigan LF; Tran K; Moss A; Swan MP
J Gastroenterol Hepatol; 2009 Sep; 24(9):1516-21. PubMed ID: 19743997
[TBL] [Abstract][Full Text] [Related]
39. [Metastasized carcinoid tumor treated with interferon and octreotide].
Szilvás A; Székely G; Szilvási I; Jakab F
Orv Hetil; 1998 Oct; 139(41):2455-8. PubMed ID: 9805460
[TBL] [Abstract][Full Text] [Related]
40. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia.
Gough DB; Thompson GB; Crotty TB; Donohue JH; Kvols LK; Carney JA; Grant CS; Nagorney DM
World J Surg; 1994; 18(4):473-9; discussion 479-80. PubMed ID: 7725731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
